Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

SellasgpsCurativeBAT11 Aug. 21 at 11:10 PM

$SLS Dr. Stergiou is a very Shrewd CEO. He/Sellas didn’t go in to a quiet period on July 7, 2026 if it was that far ought. Dr. Stergiou is a man with a master plan, Monday is a going to rude awakening for Shorts that has been talking trash about him for years. News will hit in waves and by EOM September 2026 Sellas won’t be a stand alone Co. but be part of $JNJ. Mark this post! ✌️🙏❤️‍🩹

0 · Reply

Outcomes Aug. 21 at 10:58 PM

$IBRX $MRNA $MRK $PFE $JNJ mRNA BAD. Covid jab: ‘Turbo-cancers’ Flu vax: botched trial PSS knows. https://x.com/jesslovesmjk/status/2090478010600218827?s=46

0 · Reply

Ryuk Aug. 21 at 10:28 PM

$JNJ $1.88 close. You're welcome.

0 · Reply

trachea Aug. 21 at 7:58 PM

$JNJ $SLS are you ok bro?👍😁🍀

0 · Reply

Johnmtnb2018 Aug. 21 at 7:58 PM

$SLS $JNJ BO Monday!

0 · Reply

DidYouReadThis Aug. 21 at 7:52 PM

2 heads are better than one? Care to make a guess for me to point out what I might be missing about #otlk? $MRNA $REGN $JNJ $SLS . Thank you all!

0 · Reply

Ryuk Aug. 21 at 5:21 PM

$JNJ $1.70

0 · Reply

Ryuk Aug. 21 at 4:24 PM

$JNJ $1.58

0 · Reply

TheChartiste Aug. 21 at 4:12 PM

$JNJ steady climber from here

0 · Reply

Ryuk Aug. 21 at 3:28 PM

$JNJ $1.45

0 · Reply

Oppenheimer upgrades Intuitive Surgical on lack of U.S. competition

ISRG JNJ

Aug 13, 2026, 11:15 PM EDT - 7 days ago

Expert explains why healthcare is a top-performing sector

ABBV AMGN BIIB GILD LLY MRK UNH

Aug 10, 2026, 4:27 PM EDT - 11 days ago

Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Aug 6, 2026, 6:23 PM EDT - 15 days ago

Jim Cramer highlights 5 investing themes — and the stocks to buy for each

AMAT AXP COF CRWD GS KLAC LLY

2026-08-06T10:48:29.000Z - 15 days ago

Johnson & Johnson price target raised to $287 from $270 at Guggenheim

JNJ

Aug 4, 2026, 4:05 PM EDT - 17 days ago

Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference

2026-08-04T12:50:51.000Z - 17 days ago

Johnson & Johnson announces Taubert to retire as EVP, Worldwide Chairman

JNJ

Aug 4, 2026, 8:45 AM EDT - 17 days ago

Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

Aug 3, 2026, 8:00 AM EDT - 18 days ago

Johnson & Johnson Transcript: Investor update

2026-08-03T11:00:29.000Z - 18 days ago

Johnson & Johnson price target raised to $282 from $272 at Wells Fargo

JNJ

2026-08-03T09:35:43.000Z - 18 days ago

Johnson & Johnson removed from US Conviction List at Goldman Sachs

JNJ

Aug 2, 2026, 8:00 AM EDT - 19 days ago

Inside J&J's Lab to Create a Simpler Robotic Surgery Device

2026-07-30T12:35:46.000Z - 22 days ago

Johnson & Johnson’s head & neck cancer candidate granted FDA Priority Review

JNJ

Jul 30, 2026, 8:30 AM EDT - 22 days ago

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

Jul 29, 2026, 6:13 PM EDT - 23 days ago

Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines

Jul 29, 2026, 5:42 PM EDT - 23 days ago

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

2026-07-29T21:40:31.000Z - 23 days ago

Johnson & Johnson sees Firefly, Sail Biomedicines dilute FY27 EPS by $1.36

JNJ

Jul 29, 2026, 5:38 PM EDT - 23 days ago

Johnson & Johnson lowers 2026 profit forecast

2026-07-29T21:35:31.000Z - 23 days ago

Johnson & Johnson cuts FY26 EPS view to $10.86-$11.01, consensus $11.68

JNJ

2026-07-29T21:35:19.000Z - 23 days ago

Johnson & Johnson affirms FY26 revenue view of $100.8B-$101.4B

JNJ

Jul 29, 2026, 5:28 PM EDT - 23 days ago

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Jul 29, 2026, 12:01 PM EDT - 23 days ago

Explainer: Can J&J finally put the talc litigation behind it?

2026-07-29T13:31:13.000Z - 23 days ago

Johnson & Johnson price target raised to $300 from $290 at Argus

JNJ

Jul 28, 2026, 4:31 PM EDT - 24 days ago

Johnson & Johnson offers $5.5 billion to settle remaining lawsuits over talc products linked to cancer

Jul 28, 2026, 12:26 PM EDT - 24 days ago

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

Jul 28, 2026, 1:03 AM EDT - 24 days ago

Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuit

Jul 28, 2026, 12:31 AM EDT - 24 days ago

J&J offers $5.5bn to settle baby powder lawsuits

Jul 27, 2026, 9:29 PM EDT - 24 days ago

Johnson & Johnson Agrees to Pay $5.5 Billion to Settle Talc Lawsuits

Jul 27, 2026, 6:47 PM EDT - 25 days ago

Johnson & Johnson announces $5.5 billion settlement of talc lawsuits

Jul 27, 2026, 6:31 PM EDT - 25 days ago

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

Jul 27, 2026, 5:45 AM EDT - 25 days ago

Robert Kiyosaki sees a brutal depression ahead: 3 stocks that may protect portfolios

NEM WMT

$TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma$

Jul 23, 2026, 8:30 AM EDT - 4 weeks ago

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

Jul 22, 2026, 4:33 PM EDT - 4 weeks ago

US judge casts doubt on 69,000 cases alleging J&J talc caused cancer

Jul 22, 2026, 7:21 AM EDT - 4 weeks ago

Johnson & Johnson's robotic surgery device gets US FDA marketing authorization

Jul 22, 2026, 7:00 AM EDT - 4 weeks ago

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

Jul 21, 2026, 6:30 PM EDT - 4 weeks ago

Jim Cramer says this old-school investing concept still wins — even in the AI boom

BNY CVS GS MMM WFC

Jul 16, 2026, 8:11 AM EDT - 5 weeks ago

Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

Jul 16, 2026, 8:00 AM EDT - 5 weeks ago

DePuy Synthes Acquires Expanding Innovations™

Jul 15, 2026, 12:09 PM EDT - 5 weeks ago

J&J Leverages AI and Robots to Target $100 Billion in Annual Revenue

Jul 15, 2026, 8:30 AM EDT - 5 weeks ago

Johnson & Johnson Earnings Call Transcript: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 5 weeks ago

Johnson & Johnson Slides: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 5 weeks ago

Johnson & Johnson Earnings release: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 5 weeks ago

Johnson & Johnson Quarterly report: Q2 2026

Jul 15, 2026, 7:27 AM EDT - 5 weeks ago

ASML, Intel, Johnson & Johnson, and More Stocks That Explain Today's Market

ASML INTC

Jul 15, 2026, 6:35 AM EDT - 5 weeks ago

Johnson & Johnson Hikes Guidance, Stock Falls

Jul 15, 2026, 6:33 AM EDT - 5 weeks ago

Johnson & Johnson Bumps Up Guidance as Sales Rise

Jul 15, 2026, 6:25 AM EDT - 5 weeks ago

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

Jul 15, 2026, 6:23 AM EDT - 5 weeks ago

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Jul 15, 2026, 6:20 AM EDT - 5 weeks ago

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

Jul 9, 2026, 1:00 PM EDT - 6 weeks ago

The Big 3: UNH, KO, JNJ

KO UNH

Jul 8, 2026, 7:45 AM EDT - 6 weeks ago

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jul 6, 2026, 6:29 PM EDT - 6 weeks ago

Jim Cramer says these are the 5 stocks to buy during this market rotation

PEP SBUX STZ TJX

Jun 26, 2026, 2:39 PM EDT - 2 months ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI APGE LLY MRNA SNY XBI

Jun 26, 2026, 12:35 PM EDT - 2 months ago

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Jun 25, 2026, 5:00 AM EDT - 2 months ago

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jun 15, 2026, 6:00 AM EDT - 2 months ago

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

$New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:41 AM EDT - 2 months ago

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

$New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:33 AM EDT - 2 months ago

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 11, 2026, 7:45 AM EDT - 2 months ago

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Jun 11, 2026, 2:03 AM EDT - 2 months ago

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Jun 10, 2026, 11:22 AM EDT - 2 months ago

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Jun 10, 2026, 6:20 AM EDT - 2 months ago

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Jun 9, 2026, 10:00 AM EDT - 2 months ago

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 9:20 AM EDT - 2 months ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN LLY MRK NVO PFE

Jun 8, 2026, 9:01 AM EDT - 2 months ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion

SellasgpsCurativeBAT11 Aug. 21 at 11:10 PM

0 · Reply

Outcomes Aug. 21 at 10:58 PM

$IBRX $MRNA $MRK $PFE $JNJ mRNA BAD. Covid jab: ‘Turbo-cancers’ Flu vax: botched trial PSS knows. https://x.com/jesslovesmjk/status/2090478010600218827?s=46

0 · Reply

Ryuk Aug. 21 at 10:28 PM

$JNJ $1.88 close. You're welcome.

0 · Reply

trachea Aug. 21 at 7:58 PM

$JNJ $SLS are you ok bro?👍😁🍀

0 · Reply

Johnmtnb2018 Aug. 21 at 7:58 PM

$SLS $JNJ BO Monday!

0 · Reply

DidYouReadThis Aug. 21 at 7:52 PM

2 heads are better than one? Care to make a guess for me to point out what I might be missing about #otlk? $MRNA $REGN $JNJ $SLS . Thank you all!

0 · Reply

Ryuk Aug. 21 at 5:21 PM

$JNJ $1.70

0 · Reply

Ryuk Aug. 21 at 4:24 PM

$JNJ $1.58

0 · Reply

TheChartiste Aug. 21 at 4:12 PM

$JNJ steady climber from here

0 · Reply

Ryuk Aug. 21 at 3:28 PM

$JNJ $1.45

0 · Reply

Ryuk Aug. 21 at 3:26 PM

$JNJ Lotto Play: $270 puts at $0.33.

0 · Reply

Ryuk Aug. 21 at 3:19 PM

$JNJ Lotto Play: $272.50 puts at $1.25.

0 · Reply

cykuTYTkaxa Aug. 21 at 3:04 PM

$JNJ + 3D Systems https://www.reddit.com/r/DDDInvestors/s/gxhrQpL6eH

0 · Reply

NEWBIGTECH Aug. 21 at 2:28 PM

$SLS from x. $JNJ Updated website on Aug 17, 2026.

0 · Reply

GordoHLYK13 Aug. 21 at 1:11 PM

$IGC is already in Phase 2 CALMA—this isn’t a preclinical story. If the Phase 2 topline confirms the encouraging interim efficacy and safety signals, IGC could go from overlooked micro-cap to a serious Big Pharma target for partnership, licensing, or acquisition discussions. 🚀 Phase 2 success changes the game. Big Pharma doesn’t chase potential—it chases validated clinical data. If CALMA delivers, don’t be surprised when the big boys start chasing $MRNA $LLY $JNJ

0 · Reply

SellasgpsCurativeBAT11 Aug. 21 at 12:16 PM

$JNJ $SLS Part 5. Dr. Stergiou can’t send a more blunt signal than this “SELLAS Life Sciences Group, Inc. entered a quiet period regarding any clinical updates and other corporate matters with investors and shareholders.” Other Corporate matters include M&A! ✌️🙏❤️‍🩹

0 · Reply

SellasgpsCurativeBAT11 Aug. 21 at 12:00 PM

$JNJ $SLS Part 4. Mr. Cavanaugh takes over On 9/1/26 that’s 6 trading days from today. Expecting 1 major PR before that. Stay Tuned things are about to get very interesting! ✌️🙏❤️‍🩹

0 · Reply

Quantumup Aug. 21 at 11:34 AM

Citizens reiterated $BCAX Market Outperform-$31 after Bicara recently reported 2Q26 financial results. MRUS - $GMAB $JNJ LLY MRK BMY ANZ INCY EXEL PFE SMMT Citizens said -- With Bicara's pivotal trial advancing rapidly, initial mCRC data expected in 2H26, and a cash position of $497.3MM, we believe Bicara shares represent an attractive investment opportunity, with ~55% potential downside (bear case $11) and ~93% potential upside (bull case $47).

0 · Reply

Duncan74 Aug. 21 at 10:56 AM

$SLS Merck ($MRK) has an even wider, more glaring "empty slot" in AML than $JNJ does. They are out there buying up blood-cancer assets for ET, CLL, and CML like they’re collecting Infinity Stones, yet their AML pipeline has a giant, glaring "404 Error: Not Found." 🤡 The $31B Countdown: Keytruda hits a massive patent cliff in 2028. Merck's corporate strategy right now is essentially sprinting around with a checkbook trying to plug a multi-billion dollar revenue crater. The Perfect Target: GPS already has clinical history paired with Keytruda. The NDAs are Waiting: With REGAL sitting at 78/80 events and the EAP data packages and the open-label SLS009 data packages ready to view, Merck has the cash and the sheer corporate panic to fill that vacuum overnight. But please, do keep telling me how Big Pharma isn't auditing the data room under NDAs while their crown jewel expires. The data room must be crowded. 🍿

0 · Reply

ChristinaFleming366 Aug. 21 at 7:14 AM

$MRVL $COIN $TDOC $ADBE $JNJ Marvell benefits from AI networking and custom-chip demand, Coinbase benefits from crypto trading activity, Teladoc remains focused on digital healthcare, Adobe benefits from creative software and AI adoption, and Johnson & Johnson provides diversified healthcare exposure. I'm watching AI capex, crypto volumes, patient engagement, software growth, and healthcare demand.

0 · Reply

Duncan74 Aug. 21 at 4:23 AM

$JNJ $SLS This is an absolute masterclass in corporate forensics, and it is exactly why the constant chart crying on this board is so pathetic. While the weak hands are inventing new theories, modeling the mathematical models with new assumptions, getting lost in abstract spreadsheets and sweating over intraday pennies and crying about market maker algorithms, our in-house biostatistician just laid out the exact paper trail of a classic Big Pharma buyout. Big Pharma deals don't happen by accident. They are hammered out in private closed-door J.P. Morgan meetings and trusted executive networks months before a database lock.

0 · Reply

SellasgpsCurativeBAT11 Aug. 21 at 3:06 AM

$JNJ $SLS Part 3. $SLS same 3 Top Institutional holders as $JNJ Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September 1, 2026. Very interesting Timeline of events. The latest update to J&J webpages on AML specifically are hard to ignore. So is the fact that the CEO who led AMBRX to a buyout by J&J in March 2024 (for a couple of Billion) was liking at least half a dozen or more of Dr. Stergiou's LinkedIn posts mid 2024-2025. Even with Stifel and all around, personal introductions between companies by a third party respected CEO that J&J already trusted can make a big difference. I truly believe $JNJ Deal Conversations began at November 2025 JP Morgan 1x1 conference. SELLAS Life Sciences Group participated in one-on-one (1x1) investor meetings at the J.P. Morgan U.S. Opportunities Forum on Wednesday, November 12, 2025, held at the Kimpton EPIC Hotel in Miami, FL, led by President and CEO Dr. Angelos Stergiou. ✌️🙏❤️‍🩹

1 · Reply

Market Cap	658.89B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	24.96
Forward PE	23.35
Profit Margin	28.46%
Debt to Equity Ratio	0.44

Volume	6,186,339
Avg Vol	8,125,328
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	57%
Beta	0.24
Analysts	Strong Sell
Price Target	$275.42